Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Verenium Reports Financial Results for the First Quarter Ended March 31, 2011

      -- Continued to further diversify revenue base; decreased SG&A and total debt --


      News provided by

      Verenium Corporation

      May 12, 2011, 04:00 ET

      Share this article

      Share this article


      SAN DIEGO, May 12, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the first quarter ended March 31, 2011.

      "I am pleased with the operational and financial progress made in the first quarter," said James E. Levine, President and Chief Executive Officer at Verenium. "Product revenues from our Grain and Oilseed Processing product lines continue to grow and our next-generation pipeline products have generated strong interest from potential partners. The trends towards higher commodity prices and increased demand for food and transportation fuels will continue to drive growth for products like ours, which provide the operating efficiencies customers value."

      Company Highlights

      Since the beginning of 2011, Verenium has made significant progress on both operational and financial fronts.  Recent accomplishments include:

      Operational/Industry Performance:

      Animal Health and Nutrition

      • Grew first quarter 2011 revenues from the Company's animal health and nutrition enzymes over the same period in 2010.

      Grain Processing

      • Grew first quarter 2011 revenues from the Company's grain processing enzymes, including Fuelzyme® alpha-amylase, Deltazym® GA L-E5 glucoamylase, Veretase® alpha-amylase and Xylathin™ xylanase, by 26% over the same period in 2010; and
      • Grain processing has grown to represent 30% of 2011 product revenues.

      Oilseed Processing

      • Achieved significant Purifine® phospholipase C (PLC) revenue growth over 2010 resulting from deployments by Molinos Rio de la Plata and Terminal 6, the world's two largest soybean crushing facilities, both located in Argentina.

      Manufacturing

      • Manufacturing improvement program progressed according to plan showing early signs of yield improvements.

      Corporate/Financial:

      • Increased total product revenue by 13% to $13.0 million for the quarter ended March 31, 2011, compared to $11.6 million for the same period in 2010;
      • Increased first quarter 2011 revenue from non-animal health and nutrition product lines as a percentage of product revenue from 31% in the first quarter of 2010 to 38% in the first quarter of 2011 through increasing sales of Company's newer enzymes including Xylathin™ xylanase, Veretase® alpha-amylase, Deltazym® GA L-E5 glucoamylase and Purifine® PLC;
      • Retired $30.6 million in convertible notes; and
      • Ended the quarter with unrestricted cash and cash equivalents totaling $46.2 million and convertible notes outstanding of $44.2 million.

      Financial Results

      In the commentary below, the historical results of the Company's ligno-cellulosic biofuels business for current and prior periods have been reclassified into discontinued operations as a result of the sale of the ligno-cellulosic biofuels business on September 2, 2010 to BP.

      Revenues

      Revenues for the three months ended March 31, 2011 and 2010 were as follows (in thousands):



      Three Months Ended 

      March 31,


      2011


      2010

      Revenues:




            Animal health and nutrition

      $           8,075


      $          7,954

            Grain processing

      3,894


      3,087

            All other products

      1,063


      521

                 Total product

      13,032


      11,562

      Collaborative

      364


      662

      Total revenues

      $         13,396


      $        12,224




      Total revenues for the quarter ended March 31, 2011 increased 10% to $13.4 million from $12.2 million for the same period in the prior year, with product revenues representing 95% or more of total revenues in both periods. Product revenues for the quarter ended March 31, 2011 increased 13% to $13.0 million from $11.6 million for the same period in the prior year, primarily due to an increase in revenues from grain processing enzymes, Veretase® alpha-amylase, Deltazym® GA L-E5 glucoamylase and Xylathin™ xylanase, which continued to gain traction in the grain ethanol markets and Purifine® enzyme for the soybean oil processing market, which achieved significant revenue growth over 2010.

      Product Gross Profit and Gross Margin

      Product gross profit for the quarter ended March 31, 2011 decreased 2% to $4.9 million from $5.0 million for the same period in prior year. Gross margin decreased to 38% of product revenue for the three months ended March 31, 2011, compared to 44% for the three months ended March 31, 2010.  Gross margin decreased primarily due to a decrease in the royalty on Phyzyme profit share from Danisco Animal Nutrition resulting from decreased external sales reported by Danisco, and to a lesser extent lower manufacturing yields, primarily related to early-stage commercial production of Purifine® PLC.

      Operating Expenses (excluding cost of product revenue and restructuring expense)

      Excluding cost of product revenues and restructuring total operating expenses related to continuing operations decreased to $7.1 million (including share-based compensation of $0.2 million) for the quarter ended March 31, 2011 from $8.5 million (including share-based compensation of $0.3 million) for the same period in the prior year, primarily due to reimbursement of legal fees of $1.1 million for expenses incurred during 2010 for defense of the Company's noteholder lawsuit which was settled on March 23, 2011, and initiatives to decrease general and administrative expenses, partially offset by an increase in research and development costs for continued investment in pipeline products.

      Restructuring Expense

      On March 31, 2011 the Company closed its office in Cambridge, Massachusetts, resulting in a charge of $2.8 million, consisting of employee termination costs, facilities closure costs, and employee relocation costs for several employees who were relocated to San Diego.

      Operating Loss from Continuing Operations

      Operating loss from continuing operations for the quarter ended March 31, 2011 was $4.7 million compared to $2.8 million for the same period in 2010. This increase is primarily reflective of the $2.8 million restructuring charge. Excluding the impact of restructuring, operating loss from continuing operations decreased $1.0 million, primarily due to the reimbursement of legal fees.

      Net Income (loss) from Continuing Operations

      Net income from continuing operations for the quarter ended March 31, 2011 was $3.8 million compared to a net loss of $4.1 million for the same period in 2010, on a GAAP accounting basis. Adjusted for the impact of non-cash items related to the Company's convertible debt, the Company's non-GAAP pro-forma net loss from continuing operations for the quarter ended March 31, 2011 was $5.7 million compared to $4.8 million for the same period in the prior year. The Company believes that excluding the impact of these items provides a more consistent measure of operating results.  

      Convertible Debt

      During the first quarter of 2011, the Company repurchased $30.6 million in principal amount of its outstanding convertible notes in a series of privately-negotiated transactions. To effect these repurchases, the Company paid a total of $29.7 million in cash to a group of noteholders to retire principal, plus $0.9 million of accrued interest as of the closing date.  The Company has repurchased $51.6 million in convertible notes since September 2010.

      "The repurchase of Notes has significantly reduced our debt service costs and brings our overall remaining debt to a more appropriate level for a business of our size," said Jeffrey Black, Senior Vice President and Chief Financial Officer.  "In parallel with maintaining the necessary capital to fund our business in 2011, we will continue to seek ways to opportunistically address the remaining debt."

      About Verenium

      Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

      Forward-Looking Statements

      Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

      Contacts:

      Kelly Lindenboom

      Vice President, Corporate Communications

      858-431-8580

      [email protected]

      Sarah Carmody

      Manager, Corporate Communications

      858-431-8581

      [email protected]




      Verenium Corporation

      Consolidated Statements of Operations

      (unaudited, in thousands, except per share amounts)



      Three Months Ended March 31,



      2011


      2010


      Revenues:





      Product

      $           13,032


      $         11,562


      Collaborative

      364


      662


      Total revenue

      13,396


      12,224







      Operating expenses:





      Cost of product revenue

      8,084


      6,516


      Product Gross Profit

      4,948


      5,046


      Product Gross Margin

      38%


      44%


      Research and development

      2,632


      1,451


      Selling, general and administrative

      4,500


      7,063


      Restructuring charges

      2,838


      --







      Total operating expenses

      18,054


      15,030







      Operating loss from continuing operations

      (4,658)


      (2,806)







      Other Income and Expense:





      Interest and other income

      33


      79


      Interest expense

      (1,094)


      (2,059)


      Gain on debt extinguishment upon conversion of convertible notes

      --


      598


      Gain on debt extinguishment upon repurchase of convertible notes

      11,284


      --


      Gain (loss) on net change in fair value of derivative assets and liabilities

      (1,813)


      68


      Total other income (expense), net

      8,410


      (1,314)







      Net income (loss) from continuing operations

      3,752


      (4,120)


      Discontinued Operations:





      Net income (loss) from discontinued operations,

        net of income taxes

      61


      (15,376)







      Less: Loss attributed to noncontrolling interests in

        consolidated entities – discontinued operations

      --


      7,500


      Net income (loss) attributed to Verenium

      $            3,813


      $        (11,996)


      Basic and diluted net income (loss) per share:

      Continuing Operations

      $              0.30


      $            (0.34)


      Discontinued Operations

      $                 --


      $            (1.28)


      Net income (loss) attributed to Verenium

      $             0.30


      $            (0.99)


      Shares used in computing basic and diluted net income (loss) per share

      12,604


      12,057






      Verenium Corporation

      Condensed Consolidated Balance Sheet Data

      (unaudited, in thousands)



      March 31,


      December 31,


      2011


      2010





      Cash and cash equivalents

      $          46,150


      $           87,929

      Accounts receivable, net

      9,968


      6,708

      Inventory, net

      5,772


      5,316

      Restricted cash, short term

      5,000


      --

      Other current assets  

      3,016


      2,694

      Restricted cash, long term

      --


      5,000

      Property and equipment, net  

      2,968


      3,134

      Other noncurrent assets  

      650


      976





      Total assets  

      $          73,524


      $        111,757









      Current liabilities, excluding deferred revenue, restructuring and liabilities of discontinued operations

      $          11,076


      $          16,849

      Deferred revenue, current  

      2,334


      894

      Accrued restructuring, current

      1,735


      --

      Convertible notes, at carrying value (face value of $44.2 million at March 31, 2011 and $74.7 million at December 31, 2010)

      48,593


      88,011

      Other long term liabilities  

      1,100


      1,216

      Liabilities of discontinued operations  

      966


      1,617

      Stockholders' equity  

      7,720


      3,170





      Total liabilities and stockholders' equity  

      $        73,524


      $        111,757








      Verenium Corporation

      Unaudited Supplemental and Non-GAAP Pro Forma Financial Information

      (in thousands, except per share amounts)


      The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's condensed consolidated financial statements for the three months ended March 31, 2011 and 2010, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business.


      Non-GAAP Pro Forma Net Loss From Continuing Operations


      Three Months Ended

      March 31,


      2011


      2010













      Net income (loss) from continuing operations

      $         3,752


      $           (4,120)





      Adjustments:  




      Gain on debt extinguishment upon repurchase of convertible notes

      (11,284)


      --

      Gain on debt extinguishment upon conversion of convertible notes

      --


      (598)

      (Gain) loss on net change in fair value of derivative assets and liabilities

      1,813


      (68)

      Non-GAAP pro forma net loss from continuing operations  

      $        (5,719)


      $            (4,786)





      Non-GAAP pro forma net loss from continuing operations per share

      $           (0.45)


      $               (0.40)








      SOURCE Verenium Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.